Tag: Prescription Drugs
Dapagliflozin Reduces Hospitalizations Among Patients With CKD
Reduction seen in rate of admissions due to cardiac disorders, renal and urinary disorders, metabolism and nutrition disorders, neoplasms
FDA: No Useful Monoclonal Antibody Treatments Left Against New COVID-19 Variants
Immunocompromised patients can still receive convalescent plasma
Bevacizumab, Aflibercept Compared for Neovascular AMD
At the end of one year, likelihood of being weaned off treatment was higher for eyes treated with aflibercept versus bevacizumab
More Biosimilars Marketed in Germany, Switzerland Than U.S.
Monthly treatment costs of biosimilars were higher in the United States than corresponding costs in Germany, Switzerland
No Significant Association Found for ADHD Meds, CVD Risk
Meta-analysis shows no significant associations for children, adolescents, or adults, for female patients, or for those with preexisting CVD
Deferiprone Not Beneficial for Newly Diagnosed Parkinson Disease
Greater decrease seen in nigrostriatal iron content with deferiprone, but more patients have symptom progression leading to initiation of dopaminergic therapy
Buprenorphine Use in Pregnancy May Reduce Risk for Adverse Neonatal Outcomes
Risk for preterm birth, small size for gestational age, low birth weight lower for those receiving buprenorphine versus methadone
Lecanemab Reduced Markers of Amyloid in Early Alzheimer Disease
Moderately less decline seen in cognition and function at 18 months with lecanemab versus placebo
Use of New-to-Market Neurologic Medications Reported to Be Low
Use of most new-to-market meds was <20 percent; costs for these medications were substantially larger
Convection-Enhanced Delivery of Topotecan Active in Glioblastoma
Catheter pump system capable of CED of topotecan well tolerated and active in recurrent glioblastoma
